Alnylam Pharmaceuticals, Inc.
300 Third Street
3rd Floor
Cambridge,
MA 02142
United States - Map
Phone: 617-551-8200
Fax: 617-551-8101
Web Site: http://www.alnylam.com
| Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutics based on RNA interference (RNAi). The companys lead RNAi therapeutic program includes ALN-RSV01, a phase II clinical trial product for the treatment of respiratory syncytial virus (RSV) infection. It develops RNAi therapeutics for the treatment of liver cancers, hypercholesterolemia, Huntingtons disease, and transthyretin amyloidosis. The company has collaboration and license agreements with Isis Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited for the discovery, development, and commercialization of RNAi therapeutics; with Novartis Pharma AG to discover, develop, commercialize, and manufacture compounds that function through the mechanism of RNAi; and with Biogen Idec Inc. for the discovery and development of therapeutics based on RNAi for the treatment of progressive multifocal leukoencephalopathy. It also holds license and collaboration agreements with Medtronic, Inc. to develop therapeutic products for the treatment of neurodegenerative disorders; with Kyowa Hakko for the development and commercialization of ALN-RSV01; with Cubist Pharmaceuticals, Inc. to develop and commercialize therapeutic products for the treatment of RSV; and with F. Hoffmann-La Roche Ltd. to develop and commercialize therapeutics in the areas of oncology, respiratory, metabolic, and liver diseases. The companys joint venture, Regulus Therapeutics LLC, focuses on the discovery, development, and commercialization of microRNA therapeutic that targets miR-122 for the treatment of hepatitis C virus infection. In addition, it grants its intellectual property rights licenses to biotechnology companies for the development and commercialization of RNAi therapeutics; and to research companies that commercialize RNAi reagents or services under its research product licenses. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. John K. Clarke , 54
Founder, Chairman of Board, Chairman of Nominating & Corp. Governance Committee and Member of Audit Committee |
$
30.00K | N/A | Mr. John Maraganore Ph.D., 46
Chief Exec. Officer and Exec. Director |
$
525.00K |
$
2.62M | Mr. Barry Greene , 45
Pres and Chief Operating Officer |
$
350.00K |
$
1.02M | Ms. Patricia L. Allen CPA, 47
VP of Fin. and Treasurer |
$
227.00K |
$
0 | Dr. Victor Kotelianski M.D., Ph.D., 61
Sr. VP, Distinguished Alnylam Fellow |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
